Submit Manuscript  

Article Details


Recent Progress and Development of Small Molecule Kinase Inhibitors for the Treatment of Breast Cancer

[ Vol. 16 , Issue. 1 ]

Author(s):

Debasis Das* and Jian Hong   Pages 4 - 19 ( 16 )

Abstract:


Breast cancer, the most common health burden to women globally, is considered a major cause of death for women every year. Many signal transduction pathways can cause breast cancer. The kinase inhibitors can interrupt the signaling pathways, minimize tumor growth and consequently cure the disease. The scientists have discovered many kinase inhibitors as targeted drugs for breast cancer. In recent years, the inhibitors of EGFR, HER2, VEGFR, PI3K, CDK4/6, PARP and hormone receptor have been studied well for curing breast cancer. The FDA has approved a few kinase drugs such as trastuzumab, lapatinib, neratinib, palbociclib, abemaciclib, alpelisib to treat breast cancer recently. In this review, we summarized the latest development of kinase inhibitors as breast cancer therapy.

Keywords:

Breast cancer, CDK4/6, HER2, inhibitor, kinase, PI3K, signal transduction.

Affiliation:

Discovery Chemistry Research, Arromax Pharmatech Co. Ltd. Sangtian Island Science & Technology Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, Discovery Chemistry Research, Arromax Pharmatech Co. Ltd. Sangtian Island Science & Technology Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123

Graphical Abstract:



Read Full-Text article